SMT202200471T1 - Seladelpar per il trattamento della colangite biliare primitiva - Google Patents

Seladelpar per il trattamento della colangite biliare primitiva

Info

Publication number
SMT202200471T1
SMT202200471T1 SM20220471T SMT202200471T SMT202200471T1 SM T202200471 T1 SMT202200471 T1 SM T202200471T1 SM 20220471 T SM20220471 T SM 20220471T SM T202200471 T SMT202200471 T SM T202200471T SM T202200471 T1 SMT202200471 T1 SM T202200471T1
Authority
SM
San Marino
Prior art keywords
seladelpar
treatment
primary biliary
biliary cholangitis
cholangitis
Prior art date
Application number
SM20220471T
Other languages
English (en)
Italian (it)
Inventor
Pol Boudes
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of SMT202200471T1 publication Critical patent/SMT202200471T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20220471T 2016-05-31 2017-04-26 Seladelpar per il trattamento della colangite biliare primitiva SMT202200471T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
EP17722943.2A EP3463328B1 (en) 2016-05-31 2017-04-26 Seladelpar for the treatment of primary biliary cholangitis
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
SMT202200471T1 true SMT202200471T1 (it) 2023-01-13

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220471T SMT202200471T1 (it) 2016-05-31 2017-04-26 Seladelpar per il trattamento della colangite biliare primitiva

Country Status (27)

Country Link
US (5) US10272058B2 (cg-RX-API-DMAC10.html)
EP (1) EP3463328B1 (cg-RX-API-DMAC10.html)
JP (1) JP7079735B2 (cg-RX-API-DMAC10.html)
KR (1) KR102408288B1 (cg-RX-API-DMAC10.html)
CN (2) CN121466055A (cg-RX-API-DMAC10.html)
AU (1) AU2017274293B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018074147A2 (cg-RX-API-DMAC10.html)
CA (1) CA3024155C (cg-RX-API-DMAC10.html)
CY (1) CY1125465T1 (cg-RX-API-DMAC10.html)
DK (1) DK3463328T3 (cg-RX-API-DMAC10.html)
ES (1) ES2921230T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20220903T1 (cg-RX-API-DMAC10.html)
HU (1) HUE059838T2 (cg-RX-API-DMAC10.html)
IL (1) IL263372B2 (cg-RX-API-DMAC10.html)
LT (1) LT3463328T (cg-RX-API-DMAC10.html)
MX (1) MX390417B (cg-RX-API-DMAC10.html)
NZ (1) NZ748721A (cg-RX-API-DMAC10.html)
PL (1) PL3463328T3 (cg-RX-API-DMAC10.html)
PT (1) PT3463328T (cg-RX-API-DMAC10.html)
RS (1) RS63345B1 (cg-RX-API-DMAC10.html)
RU (1) RU2765460C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201810123SA (cg-RX-API-DMAC10.html)
SI (1) SI3463328T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202200471T1 (cg-RX-API-DMAC10.html)
UA (1) UA122719C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017209865A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201808360B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MX2021005724A (es) * 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento combinado contra nafld y nash.
RS65546B1 (sr) * 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Tretman holangiopatija sa seladelparom
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法
US20260207538A1 (en) * 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE69636160D1 (de) 1995-03-06 2006-06-29 Isis Pharmaceuticals Inc Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
DK0882061T3 (da) 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
PT1725234E (pt) 2004-03-05 2013-03-04 Univ Pennsylvania Métodos com efeitos secundários reduzidos para tratamento de patologias ou doenças associadas a hiperlipidemia e hipercolesterolemia
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
CN107233337A (zh) * 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
SG183529A1 (en) 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN106470675A (zh) 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP7023371B2 (ja) 2017-09-26 2022-02-21 サイマベイ・セラピューティクス・インコーポレイテッド 胆汁うっ滞性そう痒の処置
MX2021005724A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento combinado contra nafld y nash.
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
KR102408288B1 (ko) 2022-06-10
CA3024155A1 (en) 2017-12-07
JP2019518022A (ja) 2019-06-27
UA122719C2 (uk) 2020-12-28
PL3463328T3 (pl) 2022-10-03
ZA201808360B (en) 2020-02-26
US20190255004A1 (en) 2019-08-22
WO2017209865A1 (en) 2017-12-07
ES2921230T3 (es) 2022-08-22
RU2018146504A3 (cg-RX-API-DMAC10.html) 2020-07-27
US20210220305A1 (en) 2021-07-22
BR112018074147A2 (pt) 2019-03-06
CN109195594A (zh) 2019-01-11
EP3463328A1 (en) 2019-04-10
CA3024155C (en) 2023-10-10
NZ748721A (en) 2022-04-29
IL263372B2 (en) 2023-06-01
CN121466055A (zh) 2026-02-06
US10272058B2 (en) 2019-04-30
SI3463328T1 (sl) 2022-08-31
US11596614B2 (en) 2023-03-07
US20200061006A1 (en) 2020-02-27
US20170340589A1 (en) 2017-11-30
AU2017274293B2 (en) 2022-03-31
PT3463328T (pt) 2022-07-07
AU2017274293A1 (en) 2018-12-13
LT3463328T (lt) 2022-08-10
IL263372A (en) 2018-12-31
MX2018014915A (es) 2019-04-24
CY1125465T1 (el) 2025-05-09
US20210000774A1 (en) 2021-01-07
US10813895B2 (en) 2020-10-27
US10478411B2 (en) 2019-11-19
RU2018146504A (ru) 2020-07-09
SG11201810123SA (en) 2018-12-28
HUE059838T2 (hu) 2023-01-28
RU2765460C2 (ru) 2022-01-31
MX390417B (es) 2025-03-20
EP3463328B1 (en) 2022-06-15
US11000494B2 (en) 2021-05-11
RS63345B1 (sr) 2022-07-29
JP7079735B2 (ja) 2022-06-02
KR20190015363A (ko) 2019-02-13
DK3463328T3 (da) 2022-07-04
HRP20220903T1 (hr) 2022-10-14

Similar Documents

Publication Publication Date Title
CY2025027I1 (el) Ελαφιμπρανορη για χρηση στην αντιμετωπιση πρωτοπαθους χολικης χολαγγειiτιδας
IL275482A (en) Asketamine for the treatment of depression
IL266012A (en) Combination therapy for c3 inhibition
ZA201903649B (en) Treatment for primary biliary cholangitis
SMT201900172T1 (it) Ammino triazoli sostituiti utili come inibitori della chitinasi umana
PL3506904T3 (pl) Leczenie otępienia
SI3524255T1 (sl) Sestavek za zdravljenje aken
LT3463328T (lt) Seladelparas pirminiam tulžies cholangitui gydyti
AP2016009497A0 (en) Process for the treatment of high sulphate waters
IL253617A0 (en) Snekribirock for the treatment of leprosy
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL327077A (en) Varsedanib combinations for the treatment of glioma
PL3431656T3 (pl) Sposób obróbki kamieni tłuczniowych
ZA202001536B (en) Method for the treatment of wastewaters
PL3292226T3 (pl) Sposób obróbki szlamu zawierającego żelazo
PL2937084T3 (pl) Sposób leczenia hipercholesterolemii
IL252237A0 (en) Compounds for the treatment of cancer
ZA201906542B (en) Process for the treatment of wastewater
HK40019899A (en) Compounds and methods for treatment of primary biliary cholangitis
GB201701928D0 (en) Compounds for the treatment of hyperglycaemia
PT3524255T (pt) Composição para o tratamento do acne
PT3320102T (pt) Processo para a síntese de pentostatina